Arax Advisory Partners’s Castle Biosciences CSTL Stock Holding History

Arax Advisory Partners’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7K	Buy	786 +782	+19,550%	+$17.4K	﹤0.01%	4004
2026 Q1	$99	Sell	4 -33	-89%	-$1.08K	﹤0.01%	3615
2025 Q4	$1.44K	Sell	37 -537	-94%	-$17.3K	﹤0.01%	3381
2025 Q3	$13.1K	Buy	+574	New	+$11.7K	﹤0.01%	2483
2025 Q1	–	Sell	-31	Closed	-$827	–	2751
2024 Q4	$827	Hold	31	–	–	﹤0.01%	2211
2024 Q3	$885	Hold	31	–	–	﹤0.01%	2293
2024 Q2	$675	Buy	+31	New	+$691	﹤0.01%	2278
2023 Q4	–	Sell	-12	Closed	-$203	–	1354
2023 Q3	$203	Hold	12	–	–	﹤0.01%	1282
2023 Q2	$165	Hold	12	–	–	﹤0.01%	1240
2023 Q1	$273	Hold	12	–	–	﹤0.01%	1232
2022 Q4	$282	Buy	+12	New	+$278	﹤0.01%	1224
2022 Q2	–	Sell	-12	Closed	-$1K	–	1173
2022 Q1	$1K	Hold	12	–	–	﹤0.01%	1015
2021 Q4	$1K	Buy	+12	New	+$627	﹤0.01%	988

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's CSTL Position: Q2 2026 in Review

Arax Advisory Partners increased its Castle Biosciences (CSTL) stake by 19,550% in Q2 2026, buying an estimated $17.4K and bringing the position to 786 shares worth $18.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4004.

Arax Advisory Partners first reported a position in CSTL in Q4 2021 and has held it in 13 quarters since. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Arax Advisory Partners held 786 shares of Castle Biosciences worth $18.7K as of Q2 2026.
Arax Advisory Partners bought 782 Castle Biosciences shares in Q2 2026, an estimated $17.4K.
Castle Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4004 holding.
Arax Advisory Partners first reported a position in Castle Biosciences in Q4 2021 and has held it in 13 quarters since.
177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.